Neogenomics Inc [NEO] stock is trading at $13.22, up 2.24%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NEO shares have gain 4.34% over the last week, with a monthly amount glided 11.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neogenomics Inc [NASDAQ: NEO] stock has seen the most recent analyst activity on July 30, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, William Blair downgraded its rating to Mkt Perform on July 29, 2025. On May 15, 2025, Guggenheim initiated with a Neutral rating. Leerink Partners downgraded its rating to a Market Perform but stick to its price target of $9 on April 30, 2025. The Benchmark Company downgraded its rating to a Hold. Jefferies started tracking with a Buy rating for this stock on December 10, 2024, and assigned it a price target of $22.
Neogenomics Inc [NEO] stock has fluctuated between $4.72 and $16.18 over the past year. Currently, Wall Street analysts expect the stock to reach $10.4 within the next 12 months. Neogenomics Inc [NASDAQ: NEO] shares were valued at $13.22 at the most recent close of the market. An investor can expect a potential drop of -21.33% based on the average NEO price forecast.
Analyzing the NEO fundamentals
Neogenomics Inc [NASDAQ:NEO] reported sales of 709.16M for the trailing twelve months, which represents a growth of 11.90%. Gross Profit Margin for this corporation currently stands at 0.43% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at -0.16%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.13 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Neogenomics Inc’s Current Ratio is 3.91. Also, the Quick Ratio is 3.62, while the Cash Ratio stands at 1.68. Considering the valuation of this stock, the price to sales ratio is 2.41, the price to book ratio is 2.03.
Transactions by insiders
Recent insider trading involved Olivo Alicia C, EVP, GC & Business Development, that happened on Nov 25 ’25 when 20916.0 shares were sold. Officer, ALICIA OLIVO completed a deal on Nov 25 ’25 to buy 11939.0 shares. Meanwhile, Officer ALICIA OLIVO bought 4918.0 shares on Oct 16 ’25.
